BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/20/2016 5:06:00 PM | Browse: 1617 | Download: 2181
 |
Received |
|
2016-05-26 09:05 |
|
Peer-Review Started |
|
2016-05-27 15:32 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-07-18 09:25 |
|
Revised |
|
2016-07-21 15:35 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-07-30 14:52 |
|
Second Decision by Editor-in-Chief |
|
2016-08-01 23:33 |
|
Final Decision by Editorial Office Director |
|
2016-08-05 17:54 |
|
Articles in Press |
|
2016-08-05 17:54 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-10-13 12:36 |
|
Publish the Manuscript Online |
|
2016-10-20 17:06 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yaron Ilan, Ami Ben Ya'acov, Yehudit Shabbat, Svetlana Gingis-Velitski, Einat Almon and Yoseph Shaaltiel |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Protalix Biotherapeutics and The Roman-Epstein Liver Research Foundation |
in part |
|
| Corresponding Author |
Yaron Ilan, MD, Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Ein-Karem, POB 1200, Jerusalem IL91120, Israel. ilan@hadassah.org.il
|
| Key Words |
Nonalcoholic steatohepatitis; Nonalcoholic fatty liver disease; Tumor necrosis alpha; Enbrel; Diabetes |
| Core Tip |
The BY-2 plant cell-expressed recombinant anti-tumor necrosis factor alpha (TNF) fusion protein (PRX-106) that consists of the soluble form of the human TNF receptor fused to the Fc component of a human IgG1 domain was orally administered in high-fat diet model. Altered distribution of CD4+CD25+FoxP3+ and a decrease in the intrasplenic-to-intrahepatic CD8+CD25+FoxP3+ ratio were observed. These effects were associated with a decrease in serum triglyceride levels, decrease in the aspartate aminotransferase levels, serum glucose levels, and HOMA-IR score. A decrease in hepatic triglycerides content was observed in the high dose-treated mice. The data suggest that PRX-106 may provide an oral immunotherapy for nonalcoholic steatohepatitis.
|
| Publish Date |
2016-10-20 17:06 |
| Citation |
Ilan Y, Ben Ya'acov A, Shabbat Y, Gingis-Velitski S, Almon E, Shaaltiel Y. Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis. World J Gastroenterol 2016; 22(39): 8760-8769 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i39/8760.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i39.8760 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
